RU2010119922A - Усовершенствованное противоопухолевое лечение - Google Patents
Усовершенствованное противоопухолевое лечение Download PDFInfo
- Publication number
- RU2010119922A RU2010119922A RU2010119922/15A RU2010119922A RU2010119922A RU 2010119922 A RU2010119922 A RU 2010119922A RU 2010119922/15 A RU2010119922/15 A RU 2010119922/15A RU 2010119922 A RU2010119922 A RU 2010119922A RU 2010119922 A RU2010119922 A RU 2010119922A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- tyrosine kinase
- kinase inhibitor
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract 34
- 206010028980 Neoplasm Diseases 0.000 claims abstract 19
- 201000011510 cancer Diseases 0.000 claims abstract 19
- 229940121647 egfr inhibitor Drugs 0.000 claims abstract 18
- 238000000034 method Methods 0.000 claims abstract 16
- 206010009944 Colon cancer Diseases 0.000 claims abstract 12
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 12
- 206010006187 Breast cancer Diseases 0.000 claims abstract 6
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract 6
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims abstract 6
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims abstract 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract 6
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 6
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims abstract 6
- 206010038389 Renal cancer Diseases 0.000 claims abstract 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract 6
- -1 canterinib Chemical compound 0.000 claims abstract 6
- 201000010881 cervical cancer Diseases 0.000 claims abstract 6
- 229960005395 cetuximab Drugs 0.000 claims abstract 6
- 210000001072 colon Anatomy 0.000 claims abstract 6
- 229960001433 erlotinib Drugs 0.000 claims abstract 6
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract 6
- 201000004101 esophageal cancer Diseases 0.000 claims abstract 6
- 229960002584 gefitinib Drugs 0.000 claims abstract 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims abstract 6
- 201000003911 head and neck carcinoma Diseases 0.000 claims abstract 6
- 201000010982 kidney cancer Diseases 0.000 claims abstract 6
- 229960004891 lapatinib Drugs 0.000 claims abstract 6
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims abstract 6
- 208000032839 leukemia Diseases 0.000 claims abstract 6
- 201000007270 liver cancer Diseases 0.000 claims abstract 6
- 208000014018 liver neoplasm Diseases 0.000 claims abstract 6
- 201000005202 lung cancer Diseases 0.000 claims abstract 6
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 6
- 229950008001 matuzumab Drugs 0.000 claims abstract 6
- 201000001441 melanoma Diseases 0.000 claims abstract 6
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 6
- 229960001972 panitumumab Drugs 0.000 claims abstract 6
- 206010038038 rectal cancer Diseases 0.000 claims abstract 6
- 201000001275 rectum cancer Diseases 0.000 claims abstract 6
- 229950008250 zalutumumab Drugs 0.000 claims abstract 6
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98143107P | 2007-10-19 | 2007-10-19 | |
| US60/981,431 | 2007-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010119922A true RU2010119922A (ru) | 2011-11-27 |
Family
ID=40568081
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010119922/15A RU2010119922A (ru) | 2007-10-19 | 2008-10-17 | Усовершенствованное противоопухолевое лечение |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100226919A1 (enExample) |
| EP (1) | EP2207561A2 (enExample) |
| JP (1) | JP2011500723A (enExample) |
| KR (1) | KR20100099128A (enExample) |
| CN (1) | CN101861159A (enExample) |
| AU (1) | AU2008312400A1 (enExample) |
| CA (1) | CA2703720A1 (enExample) |
| IL (1) | IL205096A0 (enExample) |
| MX (1) | MX2010004259A (enExample) |
| NZ (1) | NZ584695A (enExample) |
| RU (1) | RU2010119922A (enExample) |
| WO (1) | WO2009052379A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2252315A1 (en) * | 2008-01-30 | 2010-11-24 | Pharma Mar, S.A. | Improved antitumoral treatments |
| AU2009221120A1 (en) * | 2008-03-07 | 2009-09-11 | Pharma Mar, S.A. | Improved antitumoral treatments |
| WO2012103341A1 (en) * | 2011-01-27 | 2012-08-02 | Merrimack Pharmaceuticals, Inc. | Treatment of advanced solid stage tumors using anti-erbb3 antibodies |
| LT3615544T (lt) | 2017-04-27 | 2023-05-10 | Pharma Mar S.A. | Priešnavikiniai junginiai |
| US20230056604A1 (en) * | 2020-01-20 | 2023-02-23 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| AU658396B2 (en) * | 1991-03-06 | 1995-04-13 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Humanized and chimeric monoclonal antibodies |
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9302046D0 (en) * | 1993-02-03 | 1993-03-24 | Pharma Mar Sa | Antiumoral compound-v |
| US6274551B1 (en) * | 1994-02-03 | 2001-08-14 | Pharmamar, S.A. | Cytotoxic and antiviral compound |
| US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6391874B1 (en) * | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| WO1998050406A1 (en) * | 1997-05-09 | 1998-11-12 | The General Hospital Corporation | Cell proliferation related genes |
| JP3948501B2 (ja) * | 1997-08-07 | 2007-07-25 | Ｎｓｋワーナー株式会社 | ブレーキドラム |
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
| CN1160338C (zh) * | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| US7311924B2 (en) * | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| GB0002952D0 (en) * | 2000-02-09 | 2000-03-29 | Pharma Mar Sa | Process for producing kahalalide F compounds |
| US7473681B2 (en) * | 2000-10-31 | 2009-01-06 | Pharma Mar, S.A. | Kahalalide F |
| US20050054555A1 (en) * | 2001-10-19 | 2005-03-10 | Jose Jimeno | Kahalalide compounds for use in cancer therapy |
| GB0304367D0 (en) * | 2003-02-26 | 2003-04-02 | Pharma Mar Sau | Methods for treating psoriasis |
| CN101077885A (zh) * | 2002-10-18 | 2007-11-28 | 马尔药品公司 | 新型抗肿瘤化合物 |
| US7507708B2 (en) * | 2003-02-26 | 2009-03-24 | Pharma Mar, S.A.U. | Antitumoral compounds |
| GB0321066D0 (en) * | 2003-09-09 | 2003-10-08 | Pharma Mar Sau | New antitumoral compounds |
| GB0408958D0 (en) * | 2004-04-22 | 2004-05-26 | Pharma Mar Sa | Convergent synthesis for kahalalide compounds |
| AU2007212447B2 (en) * | 2006-02-03 | 2013-02-21 | Imclone Llc | IGF-IR antagonists as adjuvants for treatment of prostate cancer |
-
2008
- 2008-10-17 CN CN200880116576A patent/CN101861159A/zh active Pending
- 2008-10-17 WO PCT/US2008/080309 patent/WO2009052379A2/en not_active Ceased
- 2008-10-17 US US12/682,921 patent/US20100226919A1/en not_active Abandoned
- 2008-10-17 NZ NZ584695A patent/NZ584695A/en not_active IP Right Cessation
- 2008-10-17 JP JP2010530143A patent/JP2011500723A/ja active Pending
- 2008-10-17 KR KR1020107011020A patent/KR20100099128A/ko not_active Withdrawn
- 2008-10-17 CA CA2703720A patent/CA2703720A1/en not_active Abandoned
- 2008-10-17 EP EP08840671A patent/EP2207561A2/en not_active Withdrawn
- 2008-10-17 AU AU2008312400A patent/AU2008312400A1/en not_active Abandoned
- 2008-10-17 MX MX2010004259A patent/MX2010004259A/es unknown
- 2008-10-17 RU RU2010119922/15A patent/RU2010119922A/ru not_active Application Discontinuation
-
2010
- 2010-04-14 IL IL205096A patent/IL205096A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008312400A1 (en) | 2009-04-23 |
| MX2010004259A (es) | 2010-08-31 |
| KR20100099128A (ko) | 2010-09-10 |
| NZ584695A (en) | 2011-06-30 |
| IL205096A0 (en) | 2010-11-30 |
| US20100226919A1 (en) | 2010-09-09 |
| WO2009052379A3 (en) | 2009-07-23 |
| CN101861159A (zh) | 2010-10-13 |
| EP2207561A2 (en) | 2010-07-21 |
| JP2011500723A (ja) | 2011-01-06 |
| CA2703720A1 (en) | 2009-04-23 |
| WO2009052379A2 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| RU2016122654A (ru) | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| RU2014108042A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественной опухоли | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| ES2269769T3 (es) | Terapia de combinacion ee comprende zd6474 y un taxano. | |
| EA202190749A1 (ru) | Способы комбинированной терапии | |
| RU2014128513A (ru) | Раковый маркер и терапевтическая мишень | |
| RU2014108045A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2014108043A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| RU2014108049A (ru) | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли | |
| EA201071268A1 (ru) | СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА erbB | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| JP2016528251A5 (enExample) | ||
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| RU2007126978A (ru) | Комбинации терапевтических агентов для лечения рака | |
| RU2013144571A (ru) | Алинзамещенные хиназолины и способы их применения | |
| JP2017536408A5 (enExample) | ||
| RU2010140890A (ru) | Улучшенные способы противоопухолевого лечения | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| JP2014518544A5 (enExample) | ||
| RU2018138626A (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| JOP20200014A1 (ar) | توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf | |
| MX2007004549A (es) | Tratamiento combinado con bortezomib y un inhibidor de cinasa del receptor del factor de crecimiento epidermico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130516 |